Published in Eur J Nutr on November 08, 2008
Effectiveness of concomitant enteral nutrition therapy and infliximab for maintenance treatment of Crohn's disease in adults. Dig Dis Sci (2012) 2.77
Nutritional status and nutritional therapy in inflammatory bowel diseases. World J Gastroenterol (2009) 1.19
Diet affects symptoms and medication response in inflammatory bowel disease. Dig Dis Sci (2013) 0.76
Markers of inflammation and coagulation may be modulated by enteral feeding strategy. JPEN J Parenter Enteral Nutr (2012) 0.76
Inflammatory bowel disease: etiology and pathogenesis. Gastroenterology (1998) 9.58
Measurement of mitochondrial membrane potential using fluorescent rhodamine derivatives. Biophys J (1999) 5.05
Translocation of certain indigenous bacteria from the gastrointestinal tract to the mesenteric lymph nodes and other organs in a gnotobiotic mouse model. Infect Immun (1979) 4.10
Restoration of barrier function in injured intestinal mucosa. Physiol Rev (2007) 2.31
Tumour necrosis factor alpha and interleukin 1beta in relapse of Crohn's disease. Lancet (1999) 2.29
Cytokine modulation of intestinal epithelial cell restitution: central role of transforming growth factor beta. Gastroenterology (1993) 2.13
Resistance of Crohn's disease T cells to multiple apoptotic signals is associated with a Bcl-2/Bax mucosal imbalance. J Immunol (1999) 2.11
Instruction for cytokine expression in T helper lymphocytes in relation to proliferation and cell cycle progression. J Exp Med (1999) 2.09
Enteral versus parenteral nutrition: the significance of bacterial translocation and gut-barrier function. Nutrition (2000) 2.03
Epithelial restitution and wound healing in inflammatory bowel disease. World J Gastroenterol (2008) 1.95
Decreased Bax expression by mucosal T cells favours resistance to apoptosis in Crohn's disease. Gut (2001) 1.92
Definition of a lamina propria T cell responsive state. Enhanced cytokine responsiveness of T cells stimulated through the CD2 pathway. J Immunol (1995) 1.62
Role of the gut lymphatic system in multiple organ failure. Curr Opin Crit Care (2001) 1.60
Altered permeability in inflammatory bowel disease: pathophysiology and clinical implications. Curr Opin Gastroenterol (2007) 1.59
Intestinal barrier function. Curr Opin Clin Nutr Metab Care (2002) 1.51
Regulation of apoptosis during homeostasis and disease in the intestinal epithelium. Inflamm Bowel Dis (2006) 1.51
Activation and signaling status of human lamina propria T lymphocytes. Gastroenterology (1991) 1.25
Human galectin-2: novel inducer of T cell apoptosis with distinct profile of caspase activation. J Immunol (2004) 1.23
Lack of enteral nutrition--effects on the intestinal immune system. J Surg Res (2005) 1.23
Adhesion molecule cascades direct lymphocyte recirculation and leukocyte migration during inflammation. Immunol Res (2000) 1.22
Modulation of intestinal epithelial wound healing in vitro and in vivo by lysophosphatidic acid. Gastroenterology (1999) 1.16
Escherichia coli Nissle 1917 distinctively modulates T-cell cycling and expansion via toll-like receptor 2 signaling. Infect Immun (2005) 1.15
Mucosal integrity and barrier function in the pathogenesis of early lesions in Crohn's disease. J Clin Pathol (2005) 1.13
Interleukin-12 and Th1 immune response in Crohn's disease: pathogenetic relevance and therapeutic implication. World J Gastroenterol (2006) 1.04
Divergent cell cycle kinetics underlie the distinct functional capacity of mucosal T cells in Crohn's disease and ulcerative colitis. Gut (2004) 1.04
Impact of caloric intake on parenteral nutrition-associated intestinal morphology and mucosal barrier function. JPEN J Parenter Enteral Nutr (2006) 1.00
Independent modulation of enterocyte migration and proliferation by growth factors, matrix proteins, and pharmacologic agents in an in vitro model of mucosal healing. Surgery (1992) 1.00
Varied role of the gut epithelium in mucosal homeostasis. Curr Opin Gastroenterol (2007) 0.99
Intestinal permeability in patients after surgical trauma and effect of enteral nutrition versus parenteral nutrition. World J Gastroenterol (2003) 0.94
p53 negatively regulates intestinal immunity by delaying mucosal T cell cycling. J Clin Invest (2002) 0.93
Critical role of caspases in the regulation of apoptosis and proliferation of mucosal T cells. Gastroenterology (2002) 0.92
Enteral nutrition versus parenteral nutrition--the risks and benefits. Nat Clin Pract Gastroenterol Hepatol (2007) 0.91
Nutritional support and infection: does the route matter? World J Surg (1998) 0.90
Risks and benefits of nutritional support during critical illness. Annu Rev Nutr (2006) 0.84
The use of enteral nutrition in the management of Crohn's disease in adults. JPEN J Parenter Enteral Nutr (2005) 0.80
Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med (2011) 11.93
A colorectal cancer classification system that associates cellular phenotype and responses to therapy. Nat Med (2013) 6.09
The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Definitions and diagnosis. J Crohns Colitis (2010) 3.97
Comparison of adefovir and tenofovir in the treatment of lamivudine-resistant hepatitis B virus infection. Hepatology (2004) 3.70
Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 2: current management. J Crohns Colitis (2012) 3.69
The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Special situations. J Crohns Colitis (2009) 3.66
Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: a phase II trial. J Clin Oncol (2009) 3.18
Long-term efficacy of tenofovir monotherapy for hepatitis B virus-monoinfected patients after failure of nucleoside/nucleotide analogues. Hepatology (2010) 3.02
ENETS Consensus Guidelines for the management of patients with liver and other distant metastases from neuroendocrine neoplasms of foregut, midgut, hindgut, and unknown primary. Neuroendocrinology (2012) 3.00
Guidelines on the diagnosis and management of iron deficiency and anemia in inflammatory bowel diseases. Inflamm Bowel Dis (2007) 2.89
Tenofovir for patients with lamivudine-resistant hepatitis B virus (HBV) infection and high HBV DNA level during adefovir therapy. Hepatology (2006) 2.68
VEGF-A links angiogenesis and inflammation in inflammatory bowel disease pathogenesis. Gastroenterology (2008) 2.53
Chymotrypsin C (CTRC) variants that diminish activity or secretion are associated with chronic pancreatitis. Nat Genet (2007) 2.48
Pre-therapeutic dosimetry and biodistribution of 86Y-DOTA-Phe1-Tyr3-octreotide versus 111In-pentetreotide in patients with advanced neuroendocrine tumours. Eur J Nucl Med Mol Imaging (2004) 2.45
Transgenic mice rich in endogenous omega-3 fatty acids are protected from colitis. Proc Natl Acad Sci U S A (2006) 2.31
Effects of interferon alpha on vascular endothelial growth factor gene transcription and tumor angiogenesis. J Natl Cancer Inst (2003) 2.19
Epidemiological study of gastroenteropancreatic neuroendocrine tumors in Japan. J Gastroenterol (2010) 2.18
Prognostic relevance of a novel TNM classification system for upper gastroenteropancreatic neuroendocrine tumors. Cancer (2008) 2.16
Rapid and sustained relief from the symptoms of carcinoid syndrome: results from an open 6-month study of the 28-day prolonged-release formulation of lanreotide. Neuroendocrinology (2004) 2.16
Activated signal transducer and activator of transcription 3 (STAT3) supports the malignant phenotype of human pancreatic cancer. Gastroenterology (2003) 2.16
Successful recanalization of a completely obliterated esophageal stricture by using an endoscopic rendezvous maneuver. Gastrointest Endosc (2005) 2.12
Variants in CPA1 are strongly associated with early onset chronic pancreatitis. Nat Genet (2013) 2.10
Prognostic factors of long-term outcome in gastroenteropancreatic neuroendocrine tumours. Endocr Relat Cancer (2008) 2.08
Antibodies against glycoprotein 2 are novel markers of intestinal inflammation in patients with an ileal pouch. J Crohns Colitis (2013) 2.03
ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: towards a standardized approach to the diagnosis of gastroenteropancreatic neuroendocrine tumors and their prognostic stratification. Neuroendocrinology (2009) 1.92
A degradation-sensitive anionic trypsinogen (PRSS2) variant protects against chronic pancreatitis. Nat Genet (2006) 1.90
Prediction of treatment outcome in patients with chronic hepatitis C: significance of baseline parameters and viral dynamics during therapy. Hepatology (2003) 1.86
Narrow-band versus white-light high definition television endoscopic imaging for screening colonoscopy: a prospective randomized trial. Gastroenterology (2008) 1.76
Pasireotide (SOM230) shows efficacy and tolerability in the treatment of patients with advanced neuroendocrine tumors refractory or resistant to octreotide LAR: results from a phase II study. Endocr Relat Cancer (2012) 1.76
A randomised phase I study of etrolizumab (rhuMAb β7) in moderate to severe ulcerative colitis. Gut (2012) 1.73
Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 3: special situations. J Crohns Colitis (2012) 1.71
Consensus guidelines for the management of patients with digestive neuroendocrine tumors--well-differentiated jejunal-ileal tumor/carcinoma. Neuroendocrinology (2007) 1.67
Unique role of junctional adhesion molecule-a in maintaining mucosal homeostasis in inflammatory bowel disease. Gastroenterology (2008) 1.62
Enhanced innate immune responsiveness and intolerance to intestinal endotoxins in human biliary epithelial cells contributes to chronic cholangitis. Liver Int (2011) 1.57
Glucocorticoids regulate barrier function and claudin expression in intestinal epithelial cells via MKP-1. Am J Physiol Gastrointest Liver Physiol (2013) 1.56
Oxidative stress regulates vascular endothelial growth factor-A gene transcription through Sp1- and Sp3-dependent activation of two proximal GC-rich promoter elements. J Biol Chem (2002) 1.56
The majority of intestinal IgA+ and IgG+ plasmablasts in the human gut are antigen-specific. J Clin Invest (2011) 1.53
Management of pediatric ulcerative colitis: joint ECCO and ESPGHAN evidence-based consensus guidelines. J Pediatr Gastroenterol Nutr (2012) 1.52
Proteomic analysis of the inflamed intestinal mucosa reveals distinctive immune response profiles in Crohn's disease and ulcerative colitis. J Immunol (2007) 1.51
Data quality of the German screening colonoscopy registry. Endoscopy (2013) 1.48
Transforming growth factor beta 1 stimulates vascular endothelial growth factor gene transcription in human cholangiocellular carcinoma cells. Cancer Res (2003) 1.48
Prostaglandin E2 inhibits migration of colonic lamina propria fibroblasts. Inflamm Bowel Dis (2010) 1.47
Bombesin, but not amylin, blocks the orexigenic effect of peripheral ghrelin. Am J Physiol Regul Integr Comp Physiol (2006) 1.47
Cardiac surgery for carcinoid heart disease in 12 cases. Gen Thorac Cardiovasc Surg (2011) 1.46
Neuroendocrine tumors of midgut and hindgut origin: tumor-node-metastasis classification determines clinical outcome. Cancer (2011) 1.46
European evidenced-based consensus on reproduction in inflammatory bowel disease. J Crohns Colitis (2010) 1.45
TNFα inhibitors restrict T cell activation and cycling via Notch-1 signalling in inflammatory bowel disease. Gut (2011) 1.45
Autoregulation of Th1-mediated inflammation by twist1. J Exp Med (2008) 1.43
Antireflux 'barriers': problems with patient recruitment for a new endoscopic antireflux procedure. Eur J Gastroenterol Hepatol (2009) 1.43
Platelets trigger a CD40-dependent inflammatory response in the microvasculature of inflammatory bowel disease patients. Gastroenterology (2003) 1.42
Omega-3 fatty acids and their lipid mediators: towards an understanding of resolvin and protectin formation. Prostaglandins Other Lipid Mediat (2012) 1.38
Galectin-1 interacts with the {alpha}5{beta}1 fibronectin receptor to restrict carcinoma cell growth via induction of p21 and p27. J Biol Chem (2005) 1.37
Gastric hyperplasia in mice with targeted disruption of the carbonic anhydrase gene Car9. Gastroenterology (2002) 1.35
Neuroendocrine neoplasms of the gut and pancreas: new insights. Nat Rev Endocrinol (2011) 1.35
Atu027, a liposomal small interfering RNA formulation targeting protein kinase N3, inhibits cancer progression. Cancer Res (2008) 1.34
European evidence-based Consensus on the management of ulcerative colitis: Special situations. J Crohns Colitis (2008) 1.34
Results from the 2nd Scientific Workshop of the ECCO. I: Impact of mucosal healing on the course of inflammatory bowel disease. J Crohns Colitis (2011) 1.29
A Toll-like receptor 7 single nucleotide polymorphism protects from advanced inflammation and fibrosis in male patients with chronic HCV-infection. J Hepatol (2007) 1.27
Hypoxia-inducible factor 1alpha determines gastric cancer chemosensitivity via modulation of p53 and NF-kappaB. PLoS One (2010) 1.27
Human galectin-2: novel inducer of T cell apoptosis with distinct profile of caspase activation. J Immunol (2004) 1.23
Colitis-associated colon tumorigenesis is suppressed in transgenic mice rich in endogenous n-3 fatty acids. Carcinogenesis (2007) 1.23
Well-differentiated pancreatic tumor/carcinoma: insulinoma. Neuroendocrinology (2007) 1.21
Optimising monitoring in the management of Crohn's disease: a physician's perspective. J Crohns Colitis (2013) 1.20
Tacrolimus is safe and effective in patients with severe steroid-refractory or steroid-dependent inflammatory bowel disease--a long-term follow-up. Am J Gastroenterol (2006) 1.19
Hypoxia-inducible factor 1alpha mediates anoikis resistance via suppression of alpha5 integrin. Cancer Res (2008) 1.19
Current treatment of ulcerative colitis. World J Gastroenterol (2011) 1.17
EUS-guided FNA of solid pancreatic masses: high yield of 2 passes with combined histologic-cytologic analysis. Gastrointest Endosc (2009) 1.17
Escherichia coli Nissle 1917 distinctively modulates T-cell cycling and expansion via toll-like receptor 2 signaling. Infect Immun (2005) 1.15
Desacyl ghrelin inhibits the orexigenic effect of peripherally injected ghrelin in rats. Peptides (2008) 1.14
RORγt⁺ innate lymphoid cells acquire a proinflammatory program upon engagement of the activating receptor NKp44. Immunity (2013) 1.14
Effects of systemic administration of a local anesthetic on pain in acute pancreatitis: a randomized clinical trial. Pancreas (2011) 1.12
Differential priming of CD8 and CD4 T-cells in animal models of autoimmune hepatitis and cholangitis. Hepatology (2007) 1.10
Signal transducers and activators of transcription 3 signaling pathway: an essential mediator of inflammatory bowel disease and other forms of intestinal inflammation. Inflamm Bowel Dis (2005) 1.10
Survival and clinical outcome of patients with neuroendocrine tumors of the gastroenteropancreatic tract in a german referral center. Ann N Y Acad Sci (2004) 1.09
CCK inhibits the orexigenic effect of peripheral ghrelin. Am J Physiol Regul Integr Comp Physiol (2004) 1.07
A motor-driven single-use colonoscope controlled with a hand-held device: a feasibility study in volunteers. Gastrointest Endosc (2008) 1.07
Helicobacter pylori stimulates host cyclooxygenase-2 gene transcription: critical importance of MEK/ERK-dependent activation of USF1/-2 and CREB transcription factors. Cell Microbiol (2003) 1.07
Vascular endothelial growth factor-D induces lymphangiogenesis and lymphatic metastasis in models of ductal pancreatic cancer. Int J Oncol (2005) 1.06
The German NET-registry: an audit on the diagnosis and therapy of neuroendocrine tumors. Neuroendocrinology (2009) 1.05
Influence of interleukin 12B (IL12B) polymorphisms on spontaneous and treatment-induced recovery from hepatitis C virus infection. J Hepatol (2004) 1.04
Somatostatin-producing neuroendocrine tumors of the duodenum and pancreas: incidence, types, biological behavior, association with inherited syndromes, and functional activity. Endocr Relat Cancer (2008) 1.04
Adalimumab prevents barrier dysfunction and antagonizes distinct effects of TNF-α on tight junction proteins and signaling pathways in intestinal epithelial cells. Am J Physiol Gastrointest Liver Physiol (2013) 1.03
Galectin-2 and -4, but not galectin-1, promote intestinal epithelial wound healing in vitro through a TGF-beta-independent mechanism. Inflamm Bowel Dis (2008) 1.03
Prospective evaluation of pancreatic tumors: accuracy of MR imaging with MR cholangiopancreatography and MR angiography. Radiology (2002) 1.02
Angiopoietin-2 drives lymphatic metastasis of pancreatic cancer. FASEB J (2011) 1.02
Impact of Multiphase 68Ga-DOTATOC-PET/CT on therapy management in patients with neuroendocrine tumors. Neuroendocrinology (2009) 1.02
Sexual function in persons with inflammatory bowel disease: a survey with matched controls. Clin Gastroenterol Hepatol (2007) 1.02
Improving compliance to colorectal cancer screening using blood and stool based tests in patients refusing screening colonoscopy in Germany. BMC Gastroenterol (2014) 1.02
Helicobacter pylori stimulates host vascular endothelial growth factor-A (vegf-A) gene expression via MEK/ERK-dependent activation of Sp1 and Sp3. FASEB J (2003) 1.02